ENDURANCE Analysis Shows Blood-Pressure Management Reduces Stroke Risk In VAD Patients

A post-hoc analysis of the combined data from the ENDURANCE and ENDURANCE Supplemental trials shows a relationship between severely disabling stroke and one-year mortality in patients treated with Medtronic’s HeartWare HVAD as well as other left-ventricular assist devices (LVAD), including Abbott’s HeartMate II, and that blood-pressure control significantly reduces the risk of stroke events from six-months to two-years post-implant.